Colesevelam lowers glucose and lipid levels in type 2 diabetes: The clinical evidence

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

(2002) · Circulation · doi:10.1161/circ.106.25.3143 · Cited by 14,092 · see citing works

Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)

Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198 · see citing works

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · see citing works

Effects of Intensive Glucose Lowering in Type 2 Diabetes

(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888 · see citing works

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397 · see citing works

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902 · see citing works

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378 · see citing works

Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61

Basevi, V., Mario, S. D., Morciano, C., Nonino, F., & Magrini, N. (2011) · Diabetes Care · doi:10.2337/dc11-0174 · Cited by 3,058 · see citing works

The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease

(1984) · JAMA · doi:10.1001/jama.1984.03340270029025 · Cited by 2,747 · see citing works

Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation

Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678 · see citing works

Poor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed Diabetes

Saydah, S. H. (2004) · JAMA · doi:10.1001/jama.291.3.335 · Cited by 1,357 · see citing works

Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice

Zhang, Y., Lee, F. Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F. J., Willson, T. M., & Edwards, P. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506982103 · Cited by 951 · see citing works

Farnesoid X receptor is essential for normal glucose homeostasis

Ma, K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25604 · Cited by 883 · see citing works

National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007

(2008) · PsycEXTRA Dataset · doi:10.1037/e549122009-001 · Cited by 858 · see citing works

Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1

Katsuma, S., Hirasawa, A., & Tsujimoto, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.01.139 · Cited by 789 · see citing works

Lipoprotein Management in Patients With Cardiometabolic Risk

Brunzell, J. D., Davidson, M. H., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Diabetes Care · doi:10.2337/dc08-9018 · Cited by 710 · see citing works

The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice

Cariou, B., van Harmelen, K., Durán-Sandoval, D., van Dijk, T. H., Grefhorst, A., Abdelkarim, M., Caron, S., Torpier, G., Fruchart, J., Gonzalez, F. J., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510258200 · Cited by 546 · see citing works

Cholesterol and Coronary Heart Disease: Predicting Risks by Levels and Ratios

Kinosian, B., Glick, H., & Garland, G. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-9-199411010-00002 · Cited by 519 · cited 1× · see citing works

Is Glycemic Control Improving in U.S. Adults?

Hoerger, T. J., Segel, J. E., Gregg, E. W., & SAADDINE, J. B. (2007) · Diabetes Care · doi:10.2337/dc07-1572 · Cited by 477 · see citing works

Bile Acids Regulate Gluconeogenic Gene Expression via Small Heterodimer Partner-mediated Repression of Hepatocyte Nuclear Factor 4 and Foxo1

Yamagata, K., Daitoku, H., Shimamoto, Y., Matsuzaki, H., Hirota, K., Ishida, J., & Fukamizu, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314322200 · Cited by 363 · see citing works

Clinical Utility of Bile Acid Sequestrants in the Treatment of Dyslipidemia: A Scientific Review

Insull, W. (2006) · Southern Medical Journal · doi:10.1097/01.smj.0000208120.73327.db · Cited by 308 · see citing works

Colesevelam Hydrochloride (Cholestagel): A New, Potent Bile Acid Sequestrant Associated With a Low Incidence of Gastrointestinal Side Effects

Davidson, M. H., Dillon, M. A., Gordon, B., Jones, P., Samuels, J., Weiss, S., Isaacsohn, J., Toth, P., & Burke, S. K. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.16.1893 · Cited by 307 · see citing works

Diabetic Retinopathy and the Risk of Coronary Heart Disease

Cheung, N., Wang, J. J., Klein, R., Couper, D. J., Sharrett, A. R., & Wong, T. Y. (2007) · Diabetes Care · doi:10.2337/dc07-0264 · Cited by 267 · see citing works

Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy

Fonseca, V. A., Rosenstock, J., Wang, A. C., Truitt, K. E., & Jones, M. R. (2008) · Diabetes Care · doi:10.2337/dc08-0283 · Cited by 243 · see citing works

The Farnesoid X Receptor Modulates Hepatic Carbohydrate Metabolism during the Fasting-Refeeding Transition

Durán-Sandoval, D., Cariou, B., Percevault, F., Hennuyer, N., Grefhorst, A., van Dijk, T. H., Gonzalez, F. J., Fruchart, J., Kuipers, F., & Staels, B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501931200 · Cited by 241 · see citing works

Prevalence, Treatment, and Control of Diagnosed Diabetes in the U.S. National Health and Nutrition Examination Survey 1999–2004

Ong, K. L., Cheung, B. M. Y., Wong, L. Y. F., Wat, N. M. S., Tan, K. C. B., & Lam, K. S. L. (2008) · Annals of Epidemiology · doi:10.1016/j.annepidem.2007.10.007 · Cited by 232 · see citing works

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

Hanefeld, M., Brunetti, P., Schernthaner, G. H., Matthews, D. R., Charbonnel, B. H., & on behalf of the QUARTET Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.1.141 · Cited by 230 · see citing works

Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial

Goff, D. C., Gerstein, H. C., Ginsberg, H. N., Cushman, W. C., Margolis, K. L., Byington, R. P., Buse, J. B., Genuth, S., Probstfield, J. L., & Simons-Morton, D. G. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.002 · Cited by 229 · see citing works

Lower Baseline Glycemia Reduces Apparent Oral Agent Glucose-Lowering Efficacy

Bloomgarden, Z. T., Dodis, R., Viscoli, C. M., Holmboe, E. S., & Inzucchi, S. E. (2006) · Diabetes Care · doi:10.2337/dc06-1120 · Cited by 219 · see citing works

Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes

Zieve, F. J., Kalin, M. F., Schwartz, S. L., Jones, M. R., & Bailey, W. L. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.003 · Cited by 216 · see citing works

Colesevelam Hydrochloride Therapy in Patients With Type 2 Diabetes Mellitus Treated With Metformin

Bays, H. E., Goldberg, R. B., Truitt, K. E., & Jones, M. R. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.18.1975 · Cited by 212 · see citing works

Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women

Juutilainen, A., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (2007) · Diabetes Care · doi:10.2337/dc06-1747 · Cited by 209 · see citing works

Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia.

Knapp, H., Schrott, H., Ma, P., Knopp, R. H., Chin, B., Gaziano, J., Donovan, J. M., Burke, S., & Davidson, M. H. (2001) · American Journal of Medicine · doi:10.1016/s0002-9343(01)00638-6 · Cited by 201 · see citing works

Efficacy and Safety of Colesevelam in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Receiving Insulin-Based Therapy

Goldberg, R. B. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.14.1531 · Cited by 194 · see citing works

Cholestyramine Therapy for Dyslipidemia in Non–Insulin-dependent Diabetes Mellitus: A Short-Term, Double-Blind, Crossover Trial

Garg, A., & Grundy, S. M. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-6-199409150-00004 · Cited by 187 · see citing works

Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively

Hunninghake, D. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00437-3 · Cited by 176 · see citing works

Bile Acids and the Membrane Bile Acid Receptor TGR5—Connecting Nutrition and Metabolism

Thomas, C., Auwerx, J. H., & Schoonjans, K. (2008) · Thyroid · doi:10.1089/thy.2007.0255 · Cited by 154 · see citing works

Effectiveness of Colesevelam Hydrochloride in Decreasing LDL Cholesterol in Patients With Primary Hypercholesterolemia: A 24-Week Randomized Controlled Trial

Insull, W., Toth, P. D., Mullican, W. S., Hunninghake, D. B., Burke, S. K., Donovan, J. M., & Davidson, M. H. (2001) · Mayo Clinic Proceedings · doi:10.4065/76.10.971 · Cited by 138 · see citing works

Incidence and Risk Factors for Stroke in Type 2 Diabetic Patients

Giorda, C. B., Avogaro, A., Maggini, M., Lombardo, F. L., Mannucci, E., Turco, S., Alegiani, S. S., Raschetti, R., Velussi, M., Ferrannini, E., et al. (2007) · Stroke · doi:10.1161/01.str.0000260100.71665.2f · Cited by 117 · see citing works

Drug Interactions with Colesevelam Hydrochloride, a Novel, Potent Lipid-Lowering Agent

Donovan, J. M., Stypinski, D., Stiles, M. R., Olson, T. A., & Burke, S. K. (2000) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1007831418308 · Cited by 93 · see citing works

Colestimide Lowers Plasma Glucose Levels and Increases Plasma Glucagon-like Peptide-1 (7-36) Levels in Patients with Type 2 Diabetes Mellitus Complicated by Hypercholesterolemia

Suzuki, T., Oba, K., Igari, Y., Matsumura, N., Watanabe, K., Futami‐Suda, S., Yasuoka, H., Ouchi, M., Suzuki, K., Kigawa, Y., et al. (2007) · Journal of Nippon Medical School · doi:10.1272/jnms.74.338 · Cited by 93 · see citing works

Road Maps to Achieve Glycemic Control in Type 2 Diabetes Mellitus

Jellinger, P. S., Davidson, J. A., Blonde, L., EINHORN, D. F., Grunberger, G., Handelsman, Y., Hellman, R., Lebovitz, H. E., Levy, P., & Roberts, V. L. (2007) · Endocrine Practice · doi:10.4158/ep.13.3.260 · Cited by 92 · see citing works

Transient impairment of the adaptive response to fasting in FXR‐deficient mice

Cariou, B., van Harmelen, K., Durán-Sandoval, D., van Dijk, T. H., Grefhorst, A., Bouchaert, E., Fruchart, J., Gonzalez, F. J., Kuipers, F., & Staels, B. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.06.033 · Cited by 81 · see citing works

FXR‐deficiency confers increased susceptibility to torpor

Cariou, B., Bouchaert, E., Abdelkarim, M., Dumont, J., Caron, S., Fruchart, J., Burcelin, R., Kuipers, F., & Staels, B. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.09.064 · Cited by 35 · see citing works

Interpreting the Joslin diabetes center and joslin clinic clinical nutrition guideline for overweight and obese adults with type 2 diabetes

Giusti, J., & RIZZOTTO, J.-A. M. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0014-y · Cited by 22 · see citing works

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919 · see citing works

ESC/EAS Guidelines for the management of dyslipidaemias

Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549 · see citing works

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207 · see citing works

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162 · see citing works

Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)

Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J. P., Dralle, H., Ebeling, P. R., Melmed, S. K., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,473 · see citing works

Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer

Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C., Hamilton, J. K., HAY, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,253 · see citing works

Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY

Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., DeFronzo, R. A., EINHORN, D. F., Fonseca, V. A., et al. (2016) · Endocrine Practice · doi:10.4158/ep151126.cs · Cited by 874 · see citing works

ESC/EAS Guidelines for the management of dyslipidaemias

Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706 · see citing works

Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association

Joseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660 · see citing works

American Association of Clinical Endocrinologists and American College of Endocrinology – Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan – 2015 — Executive Summary

Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G. E., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S. E., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 631 · see citing works

Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary

Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598 · see citing works

Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy

Chiang, J. Y. L., & Ferrell, J. M. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00223.2019 · Cited by 580 · see citing works

American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015

Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559 · see citing works

Management of type 2 diabetes: new and future developments in treatment

Tahrani, A. A., Bailey, C. J., Prato, S. D., & Barnett, A. H. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60207-9 · Cited by 532 · see citing works

American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.

Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507 · see citing works

Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary

Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., DeFronzo, R. A., EINHORN, D. F., Fonseca, V. A., et al. (2018) · Endocrine Practice · doi:10.4158/cs-2017-0153 · Cited by 499 · see citing works

Bile acids in glucose metabolism in health and disease

Shapiro, H., Kolodziejczyk, A. A., Halstuch, D., & Elinav, E. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171965 · Cited by 467 · see citing works

Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2017 executive summary

Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435 · see citing works

Diabetes Dyslipidemia

Schofield, J. D., Liu, Y., Rao‐Balakrishna, P., Malik, R. A., & Soran, H. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0167-x · Cited by 430 · see citing works

Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells

Trabelsi, M.-S., Daoudi, M., Prawitt, J., Ducastel, S., Touche, V., Sayin, S. I., Perino, A., Brighton, C. A., Sebti, Y., Kluza, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms8629 · Cited by 404 · see citing works

Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus

Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398 · see citing works

Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis

Chiang, J. Y. L., & Ferrell, J. M. (2020) · Liver Research · doi:10.1016/j.livres.2020.05.001 · Cited by 303 · see citing works

Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary.

Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297 · see citing works

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M. A., Peters, A. L., Τσάπας, Α., Wender, R. C., & Matthews, D. R. (2012) · Diabetes Spectrum · doi:10.2337/diaspect.25.3.154 · Cited by 290 · see citing works

American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement - Executive Summary

Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garvey, W. T., et al. (2013) · Endocrine Practice · doi:10.4158/ep13176.cs · Cited by 280 · see citing works

American Association of Clinical Endocrinologists’ Comprehensive Diabetes Management Algorithm 2013 Consensus Statement

Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garvey, W. T., et al. (2013) · Endocrine Practice · doi:10.4158/ep13176.csuppl · Cited by 219 · see citing works

DrugNet: Network-based drug–disease prioritization by integrating heterogeneous data

Martínez, V., Navarro, C., Cano, C., Fajardo, W., & Blanco, A. J. (2015) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2014.11.003 · Cited by 213 · see citing works

ESC/EAS Guidelines for the management of dyslipidaemias

Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.012 · Cited by 192 · see citing works

NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient

Cheeley, M. K., Saseen, J. J., Agarwala, A., Ravilla, S., Ciffone, N., Jacobson, T. A., Dixon, D. L., & Maki, K. C. (2022) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2022.05.068 · Cited by 197 · see citing works

Links between Thyroid Disorders and Glucose Homeostasis

Eom, Y. S., Wilson, J. R., & Bernet, V. J. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0013 · Cited by 176 · see citing works

Increased Bile Acid Synthesis and Impaired Bile Acid Transport in Human Obesity

Haeusler, R. A., Camastra, S., Nannipieri, M., Astiarraga, B., Castro‐Perez, J. M., Xie, D., Wang, L., Chakravarthy, M. V., & Ferrannini, E. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2583 · Cited by 144 · see citing works

Endothelial Dysfunction in Diabetes: Pathogenesis, Significance, and Treatment

Hamilton, S. J., & Watts, G. F. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.133 · Cited by 139 · see citing works

Demystifying the management of hypertriglyceridaemia

Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.140 · Cited by 115 · see citing works

Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes

Verspohl, E. J. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003319 · Cited by 99 · see citing works

Triglycerides and atherogenic dyslipidaemia: Extending treatment beyond statins in the high-risk cardiovascular patient

Watts, G. F., & Karpe, F. (2011) · Heart · doi:10.1136/hrt.2010.204990 · Cited by 97 · see citing works

Therapeutic targeting of bile acids

Camilleri, M., & Gores, G. J. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00121.2015 · Cited by 87 · see citing works

DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases

Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., Cherney, D. Z. I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155931 · Cited by 93 · see citing works

Consensus statement on management of dyslipidemia in Indian subjects

Chandra, K. S., Bansal, M., Nair, T., Iyengar, S. S., Gupta, R., Manchanda, S. C., Mohanan, P. P., Rao, V. D., Manjunath, C. N., Sawhney, J. P. S., et al. (2014) · Indian Heart Journal · doi:10.1016/j.ihj.2014.12.001 · Cited by 84 · see citing works

Lipid-lowering in diabetes: An update

Chait, A., Eckel, R. H., Vrablı́k, M., & Zambon, A. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117313 · Cited by 71 · see citing works

Bile Acid and Cholesterol Metabolism in Atherosclerotic Cardiovascular Disease and Therapy

Chiang, J. Y. L., Ferrell, J. M., Wu, Y., & Boehme, S. (2020) · Cardiology Plus · doi:10.4103/2470-7511.305419 · Cited by 61 · see citing works

Guía de la ESC/EAS sobre el manejo de las dislipemias

Reiner, Ž., Catapano, A. L., Backer, G. D., Graham, I. M., Taskinen, M., Wiklund, O., Agewall, S., Alegría, E., Chapman, M. J., Durrington, P. N., et al. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.09.014 · Cited by 64 · see citing works

DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases

Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64 · see citing works

Nonstatin Low-Density Lipoprotein–Lowering Therapy and Cardiovascular Risk Reduction—Statement From <i>ATVB</i> Council

Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63 · see citing works

Cardiovascular safety profile of currently available diabetic drugs.

Azimova, K., Juan, Z. T. S., & Mukherjee, D. (2014) · PubMed Central · Cited by 58 · see citing works

Circulating miRNAs as a Predictive Biomarker of the Progression from Prediabetes to Diabetes: Outcomes of a 5-Year Prospective Observational Study

Sidorkiewicz, I., Niemira, M., Maliszewska, K., Erol, A., Bielska, A., Szalkowska, A., Adamska-Patruno, E., Szczerbiński, Ł., Górska, M., & Kretowski, A. J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072184 · Cited by 57 · see citing works

Diabetic dyslipidaemia

Soran, H., Schofield, J. D., Adam, S., & Durrington, P. N. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000318 · Cited by 57 · see citing works

Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders

Camilleri, M., Vázquez‐Roque, M. I., Carlson, P., Burton, D. B., Wong, B. S., & Zinsmeister, A. R. (2011) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2011.01772.x · Cited by 56 · see citing works

A Recent Achievement In the Discovery and Development of Novel Targets for the Treatment of Type-2 Diabetes Mellitus

Belete, T. M. (2020) · Journal of Experimental Pharmacology · doi:10.2147/jep.s226113 · Cited by 56 · see citing works

Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2015 Executive Summary

Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garber, J. R., et al. (2015) · Endocrine Practice · doi:10.4158/ep151063.cs · Cited by 55 · see citing works

Terpenoids as potential phytoconstituent in the treatment of diabetes: From preclinical to clinical advancement.

Roy, S., Ghosh, A., Majie, A., Karmakar, V., Das, S., Dinda, S. C., Bose, A., & Gorain, B. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155638 · Cited by 48 · see citing works

Type 2 Diabetes Mellitus

Polonsky, K. S., & Burant, C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00031-9 · Cited by 50 · see citing works

The Liver under the Spotlight: Bile Acids and Oxysterols as Pivotal Actors Controlling Metabolism

Lefort, C., & Cani, P. D. (2021) · Cells · doi:10.3390/cells10020400 · Cited by 43 · see citing works

Dyslipidemia in diabetes

Kalra, S., & Raizada, N. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.11.002 · Cited by 55 · see citing works

Management of diabetes mellitus in chronic kidney disease

Garla, V. V., Kanduri, S. R., Yanes-Cardozo, L. L., & Lien, L. F. (2019) · Minerva Endocrinology · doi:10.23736/s0391-1977.19.03015-3 · Cited by 41 · see citing works

Mechanisms of current therapies for diabetes mellitus type 2

Thulé, P. M. (2012) · AJP Advances in Physiology Education · doi:10.1152/advan.00094.2012 · Cited by 40 · see citing works

Bile Acid Metabolism in Health and Disease

Li, T., & Chiang, J. Y. L. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch23 · Cited by 40 · see citing works

Colesevelam for type 2 diabetes mellitus: an abridged Cochrane review

Ooi, C. P., & Loke, S. C. (2014) · Diabetic Medicine · doi:10.1111/dme.12295 · Cited by 39 · see citing works

Colesevelam for type 2 diabetes mellitus.

Ooi, C. P., & Loke, S. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009361.pub2 · Cited by 43 · see citing works

The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and ameliorates obesity and insulin resistance in diabetic mice

Hamada, Y., Nagasaki, H., Fuchigami, M., Furuta, S., Seino, Y., Nakamura, J., & Oiso, Y. (2012) · Metabolism · doi:10.1016/j.metabol.2012.10.015 · Cited by 37 · see citing works

Clinical Management of Elderly Patients with Type 2 Diabetes Mellitus

Pratley, R. E., & Gilbert, M. P. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.01.2526 · Cited by 33 · see citing works

Integrative roles of microRNAs in lipid metabolism and dyslipidemia

Sedgeman, L. R., Michell, D. L., & Vickers, K. C. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000603 · Cited by 33 · see citing works

Diabetic dyslipidaemia

Thambiah, S. C., & Lai, L. C. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00248 · Cited by 33 · see citing works

Effects of colesevelam on LDL‐C, A1c and GLP‐1 levels in patients with type 1 diabetes: a pilot randomized double‐blind trial

Garg, S. K., Ritchie, P. J., Moser, E. G., Snell‐Bergeon, J. K., Freson, B. J., & Hazenfield, R. M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01320.x · Cited by 30 · see citing works

Type 2 Diabetes Mellitus

Buse, J. B., Polonsky, K. S., & Burant, C. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00031-6 · Cited by 28 · see citing works

Update on Safety Issues Related to Antihyperglycemic Therapy

Carpio, G., & Fonseca, V. A. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.2.92 · Cited by 27 · see citing works

Plasma bile acid changes in type 2 diabetes correlated with insulin secretion in two‐step hyperglycemic clamp

Wang, S., Deng, Y., Xie, X., Ma, J., Xu, M., Zhao, X., Gu, W., Hong, J., Wang, W., Xu, G., et al. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12771 · Cited by 25 · see citing works

Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update

Alsayed, N., Almahmeed, W. A., Alnouri, F., Al-Waili, K., Sabbour, H. M., Sulaiman, K., Zubaid, M., Ray, K. K., & Al‐Rasadi, K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.11.022 · Cited by 23 · see citing works

Current and Emerging Treatment Options in Diabetes Care

Clemmensen, C., Müller, T. D., Finan, B., Tschöp, M. H., & DiMarchi, R. D. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_7 · Cited by 22 · see citing works

Cholesterol-Lowering Drugs

Albuquerque, E. L., Fulco, U. L., Caetano, E. W. S., & Freire, V. N. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108774956.011 · Cited by 21 · see citing works

Association among Microalbuminuria and Oxidative Stress Biomarkers in Patients with Type 2 Diabetes

Vicentini, J. T., Valentini, J., Grotto, D., Paniz, C., Roehrs, M., Brucker, N., Charão, M. F., Moro, A. M., Tonello, R., Moreira, A. P., et al. (2011) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31820eea24 · Cited by 21 · see citing works

Novel bile acid sequestrant: A biodegradable hydrogel based on amphiphilic allylamine copolymer

Wang, X., Jing, S., Qiu, X., Zhao, S., Liu, Y., & Tan, Y. (2016) · Chemical Engineering Journal · doi:10.1016/j.cej.2016.06.104 · Cited by 21 · see citing works

Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East

Sayed, N., Waili, K. A., Alawadi, F., Al-Ghamdi, S. M. G., Almahmeed, W. A., Alnouri, F., Rukhaimi, M. A., Al‐Rasadi, K., Awan, Z. A., Farghaly, M., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.081 · Cited by 21 · see citing works

In Vitro Bile Acid Binding Capacities of Red Leaf Lettuce and Cruciferous Vegetables

Yang, I. F., Jayaprakasha, G. K., & Patil, B. S. (2017) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.7b02540 · Cited by 20 · see citing works

Intestinal bile acid sequestration improves glucose control by stimulating hepatic miR-182-5p in type 2 diabetes

Sedgeman, L. R., Beysen, C., Allen, R. M., Ramirez Solano, M. A., Turner, S. M., & Vickers, K. C. (2018) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00238.2018 · Cited by 22 · see citing works

Hypoglycemic Potential of Current and Emerging Pharmacotherapies in Type 2 Diabetes Mellitus

Brunton, S. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2570 · Cited by 19 · see citing works

A New Approach to Glucose Control in Type 2 Diabetes: The Role of Kidney Sodium-Glucose Co-transporter 2 Inhibition

Basile, J. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.07.2302 · Cited by 18 · see citing works

ε3/4 genotype of the apolipoprotein E is associated with higher risk of Alzheimer's disease in patients with type 2 diabetes mellitus

Tang, Y., Li, Y., Zhang, M., Chen, Y., & Sun, Q. (2019) · Gene · doi:10.1016/j.gene.2019.03.024 · Cited by 18 · see citing works

Advances in Pharmacologic Therapies for Type 2 Diabetes

Morsink, L. M., Smits, M. M., & Diamant, M. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0302-8 · Cited by 18 · see citing works

Current therapeutic approaches in the management of hyperglycemia in chronic renal disease

Garla, V. V., Yanes-Cardozo, L. L., & Lien, L. F. (2017) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-017-9416-1 · Cited by 17 · see citing works

Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes

Goswami, G., Shinkazh, N., & Davis, N. J. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3020595 · Cited by 16 · see citing works

Safety review of combination drugs for hyperlipidemia

Farnier, M. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.540237 · Cited by 15 · see citing works

Risks and Benefits of Statin Use in Young People with Type 1 Diabetes

Bjornstad, P., & Wadwa, R. P. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0499-8 · Cited by 15 · see citing works

ADA-EASD diabetes guidance: individualised treatment of hyperglycaemia

Day, C. (2012) · The British Journal of Diabetes · doi:10.1177/1474651412450477 · Cited by 14 · see citing works

A Comprehensive Review of Novel Drug–Disease Models in Diabetes Drug Development

Gaitonde, P., Garhyan, P., Link, C., Chien, J. Y., Trame, M. N., & Schmidt, S. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0359-y · Cited by 12 · see citing works

Lower Risk of Major Cardiovascular Events Associated with Adherence to Colesevelam HCI

Ye, X., Qian, C., Liu, J., & Peter, W. L. S. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1317 · Cited by 12 · see citing works

Adenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapy

Dutta, D., Kalra, S., & Sharma, M. (2016) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.191007 · Cited by 12 · see citing works

Glycerol and its derivatives as potential C-3 bio-based building blocks for accessing active pharmaceutical ingredients

Morodo, R., Bovy, L., Silva-Brenes, D. V., & Monbaliu, J. M. (2024) · Green Chemistry · doi:10.1039/d4gc01957a · Cited by 11 · see citing works

Republished review: Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient

Watts, G. F., & Karpe, F. (2011) · Postgraduate Medical Journal · doi:10.1136/pgmj.2010.204990rep · Cited by 11 · see citing works

Sodium glucose co-transporter 2 inhibitors: A novel approach to the management of type 2 diabetes mellitus

Davis, C. S., Fleming, J. W., & Warrington, L. E. (2014) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12135 · Cited by 9 · see citing works

Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?

Watts, G. F., & Karpe, F. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.61 · Cited by 9 · see citing works

Associations Between the Apolipoprotein E ε4 Allele and Reduced Serum Levels of High Density Lipoprotein a Cognitively Normal Aging Han Chinese Population

Li, W., Li, Y., Qiu, Q., Sun, L., Yue, L., Li, X., & Xiao, S. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00827 · Cited by 9 · see citing works

Glucose-lowering effect of colestimide is associated with baseline HbA1c in type 2 diabetic patients with hypercholesterolemia

Yamakawa, T., Kaneko, T., Shigematu, E., Kawaguchi, J., Kadonosono, K., Morita, S., & Terauchi, Y. (2011) · Endocrine Journal · doi:10.1507/endocrj.k10e-255 · Cited by 8 · see citing works

The Kidney as a Treatment Target for Type 2 Diabetes

Dokken, B. B. (2012) · Diabetes Spectrum · doi:10.2337/diaspect.25.1.29 · Cited by 7 · see citing works

Repurposing of Drugs for Cardiometabolic Disorders: An Out and Out Cumulation

Wasim, R., Ansari, T. M., Siddiqui, M. H., Ahsan, F., Shamim, A., Singh, A. N., Shariq, M., Anwar, A., Siddiqui, A. R., & Parveen, S. (2023) · Hormone and Metabolic Research · doi:10.1055/a-1971-6965 · Cited by 7 · see citing works

Combination Therapy When Metformin Is Not an Option for Type 2 Diabetes

Goldman, J. D. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015572653 · Cited by 7 · see citing works

Type 2 Diabetes Treatment Recommendations Update: Appropriate Use of Dipeptidyl Peptidase-4 Inhibitors

Cornell, S. A. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000414 · Cited by 8 · see citing works

Glucose Control and Cardiovascular Outcomes in Clinical Trials of Sodium Glucose Co-transporter 2 Inhibitor Treatments in Type 2 Diabetes

OLIVEROS, R. A., Pham, S. V., Bailey, S. R., & CHILTON, R. J. (2014) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2014.10.02.117 · Cited by 6 · see citing works

Harnessing Drug Repurposing for Exploration of New Diseases: An Insight to Strategies and Case Studies

Jain, P., Jain, S. K., & Jain, M. (2020) · Current Molecular Medicine · doi:10.2174/1566524020666200619125404 · Cited by 6 · see citing works

High-fat diet promotes gestational diabetes mellitus through modulating gut microbiota and bile acid metabolism

Yao, L., Zhou, X., Jiang, X., Chen, H., Li, Y., Xiao, X., Tang, Y., Zhang, H., & Qiao, P. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1480446 · Cited by 5 · see citing works

The Role of Anti-obesity Drugs in Patients with Type 2 Diabetes

Hollander, P. (2013) · US Endocrinology · doi:10.17925/use.2013.09.02.101 · Cited by 4 · see citing works

The Use of Colesevelam HCl in Patients with Type 2 Diabetes Mellitus: Combining Glucose- and Lipid-Lowering Effects

Goldfine, A. B., & Fonseca, V. A. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.05.suppl53.288 · Cited by 6 · see citing works

Review of studies on the effect of bile acid sequestrants in patients with type 2 diabetes mellitus

Levy, P. (2010) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2010.0087 · Cited by 15 · see citing works

Colesevelam hydrochloride: A bile acid sequestrant for glycemic control and treatment of dyslipidemia in Type 2 diabetes mellitus

Surampudi, P. N., Nagireddy, P., & Fonseca, V. (2009) · Therapy · doi:10.2217/thy.09.17 · Cited by 1 · see citing works

Colesevelam for type 2 diabetes mellitus: an abridged Cochrane review

Ooi, C. P., & Loke, S. C. (2014) · Diabetic Medicine · doi:10.1111/dme.12295 · Cited by 39 · see citing works

Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam – a clinical perspective

Goldberg, R. B. (2009) · Dove Medical Press (Taylor and Francis Group)